Your browser doesn't support javascript.
loading
Inception and deprescribing of statins in people aged over 80 years: cohort study.
Gulliford, Martin; Ravindrarajah, Rathi; Hamada, Shota; Jackson, Stephen; Charlton, Judith.
Afiliação
  • Gulliford M; King's College London, Department of Primary Care and Public Health Sciences, London, UK.
  • Ravindrarajah R; National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust, London, UK.
  • Hamada S; King's College London, Department of Primary Care and Public Health Sciences, London, UK.
  • Jackson S; King's College London, Department of Primary Care and Public Health Sciences, London, UK.
  • Charlton J; Research Department, Institute for Health Economics and Policy, Association for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan.
Age Ageing ; 46(6): 1001-1005, 2017 11 01.
Article em En | MEDLINE | ID: mdl-29088364
ABSTRACT

Objective:

statin use over the age of 80 years is weakly evidence-based. This study aimed to estimate rates of statin inception and deprescribing by frailty level in people aged 80 years or older.

Methods:

a cohort of 212,566 participants aged ≥80 years was sampled from the UK Clinical Practice Research Datalink. Statin inception was defined as a first-ever prescription in a non-statin user; deprescribing was defined as a last ever statin prescription more than 6 months before the end of participant records. Rates were estimated in a time-to-event framework allowing for mortality as a competing risk. Co-variates were age, gender, frailty category and prevention type.

Results:

prevalent statin use increased from 2001-5 (9.9%) to 2011-15 (49.3%). Inception of statins in never-users was low overall at 2.4% per year (95% confidence interval (CI) 2.2-2.6%) and declined with age. Deprescribing of statins in current users occurred at a rate of 5.6% (95% CI 5.4-5.9%) per year overall and increased with age, reaching 17.8% per year (95% CI 6.7-28.9%) among centenarians. Deprescribing was slightly higher for primary prevention (6.5% per year) than secondary prevention (5.2% per year) indications (P < 0.001). Deprescribing increased with frailty level being 5.0% per year in 'fit' participants and 7.1% in 'severe' frailty (P < 0.001).

Conclusions:

statin use has increased in the over 80s but deprescribing is common and increases with age and frailty level. These paradoxical findings highlight a need for better evidence to inform statin use and discontinuation for people aged ≥80 years.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Dislipidemias / Lipídeos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Female / Humans / Male País como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Dislipidemias / Lipídeos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Female / Humans / Male País como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article